#485 — The New Science of Cancer

Cancer research has shifted from viewing the disease as a monolith to recognizing every specimen as a unique genetic entity, though all share fundamental traits like uncontrolled cell division and nutrient hijacking. Prevention remains difficult due to the lack of reliable biomarkers, yet the identification of "inflammogens"—substances that create chronic inflammation—provides a promising new framework for risk reduction. While liquid biopsies and whole-body MRIs offer early detection potential, they are currently plagued by high false-positive rates that necessitate careful Bayesian interpretation of risk. AI is increasingly vital as a companion tool in diagnostics and drug discovery, helping to identify targets and optimize clinical trials. Despite these technological advancements, the US medical ecosystem faces significant instability, exacerbated by supply chain fragility and the erosion of institutional support for scientific innovation.